US.VTRS · Viatris

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.433158201984822,
        "turnoverUsdM": 114.84947252999999,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.VTRS",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 16.2964,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 4.9,
      "take_profit_price": 18.1067,
      "target_multiplier": 1.9,
      "technical_strength": 1.85,
      "take_profit_percent": 5.7
    },
    "positionPoints": 1.4,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.866316403969644,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 65.6,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 56.6,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 9
  },
  "market": {
    "ma20": 16.6645,
    "ma50": 16.7986,
    "close": 17.13,
    "prevClose": 17.02,
    "avgVolume20": 7365639,
    "volumeRatio": 0.91,
    "changePercent": 0.65
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 9,
    "details": {
      "ret_5d": 0.04578754578754585,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 9,
      "vcp_bonus": 0,
      "vol_ratio": 0.9166464094062959,
      "ret_points": 8,
      "vol_points": 0,
      "range_ratio": 0.5335069447430868,
      "volat_points": 0,
      "day_range_pct": 0.012551079976649147,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 65.6,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 44,
        "contribution": 2.2
      },
      {
        "raw": 12.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 62,
        "contribution": 12.4
      },
      {
        "raw": 9.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 64,
        "contribution": 9.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.2,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 72,
        "contribution": 7.2
      },
      {
        "raw": 21.2,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 70.67,
        "contribution": 21.2
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 56.6,
    "details": [
      "基本面分析總分: 2.2/5分",
      "資金流分析總分: 12.4/20分",
      "市場環境分析總分: 9.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.2/10分",
      "技術信號分析總分: 21.2/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.2,
      "資金流": 12.4,
      "市場環境": 9.6,
      "情緒分析": 2,
      "技術信號": 21.2,
      "風險管理": 7.2
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 1,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 114.84947252999999,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 2.4,
          "obvPoints": 2.4,
          "vwapPoints": 3.2,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.VTRS",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 17.71
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 712.7094935,
                "ma50": 709.9877978999997,
                "name": "QQQ",
                "close": 716.91998,
                "points": 2
              },
              "spy": {
                "ma20": 764.3489924499997,
                "ma50": 759.53139858,
                "name": "SPY",
                "close": 762.59998,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.433158201984822,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 1,
              "negativeHits": 0,
              "positiveHits": 0,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141365293,
                "url": "https://finnhub.io/api/news?id=0cfe80e9f499516427ef257e6ba453fe5c12a498ea2cf0aefb7607639c325b97",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Why recent generic drug earnings matter for Viatris stock Recent earnings across the generic drug industry highlighted steady demand alongside pricing and supply challenges, putting fresh attention on how Viatris (VTRS) is using new launches, product mix, and cost discipline to support its business. At a share price of US$16.34, Viatris has seen some short term pressure, with the 1 day share price return declining 3.26% and the 1 month share price return down 8.31%. However, the year to date...",
                "category": "company",
                "datetime": 1787994714,
                "headline": "Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough?"
              }
            ],
            "raw_source": [
              {
                "id": 142197168,
                "url": "https://finnhub.io/api/news?id=4ded9287680153405d14690cb18989c70c791fc2a8bd7ad575a7949ac7d765c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Gilead Sciences (NASDAQ:GILD) has expanded six existing royalty-free voluntary licensing agreements to include an investigational once-yearly formulation of lenacapavir for HIV prevention, the company announced. The expanded agreements cover 120 countries with high HIV incidence, primarily low- and lower-middle-income nations.",
                "category": "company",
                "datetime": 1789566407,
                "headline": "Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation"
              },
              {
                "id": 142227126,
                "url": "https://finnhub.io/api/news?id=424da783644caf72eeb16f1f7ee06096d4f194d69f32c0158e77efdd6733d550",
                "image": "",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Piper Sandler  analyst David Amsellem   maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $12 to $13.",
                "category": "company",
                "datetime": 1789565516,
                "headline": "Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13"
              },
              {
                "id": 142194247,
                "url": "https://finnhub.io/api/news?id=e203dbba0dcc330fdc4ec70f010ae113203132ddd0bbc1a533b26c2ce2b4e643",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS) in patients receiving treatment for airway obstruction, and approval for narcolepsy (type 1 and 2 – with and without cataplexy). WAKIX is the first histamine H3 receptor antagonist/inverse agonist approved in Japan fo",
                "category": "company",
                "datetime": 1789556340,
                "headline": "Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome"
              },
              {
                "id": 142196130,
                "url": "https://finnhub.io/api/news?id=f143f92a40278c622263b1c06a5de75fc154cd2b5196e524a4d62f3b3684531f",
                "image": "",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Approval Addresses High Unmet Medical Need and Further Advances Viatris' Innovative Portfolio in JapanPITTSBURGH, Sept. 16, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today",
                "category": "company",
                "datetime": 1789542105,
                "headline": "Viatris Secures Japan Approval For WAKIX In Treating Excessive Daytime Sleepiness Linked To Sleep Apnea And Narcolepsy"
              },
              {
                "id": 142139504,
                "url": "https://finnhub.io/api/news?id=892ee473a89448e463e9ebabbdd3627fdd3c2e2cad825c716923497669bcd3f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 30% gain over the past six months, beating the S&P 500 by 16.7 percentage points.",
                "category": "company",
                "datetime": 1789399410,
                "headline": "3 Healthcare Stocks That Fall Short"
              },
              {
                "id": 142027870,
                "url": "https://finnhub.io/api/news?id=6a1fdabe635c8197917aa56e385df63d7662ef7d7180a580403efab69d9e90bc",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2232494006/image_2232494006.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "Viatris' Q2 showed better earnings quality, with adjusted net income and EPS up 11% while free cash flow doubled year-over-year. Click here to read more.",
                "category": "company",
                "datetime": 1788965225,
                "headline": "Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive"
              },
              {
                "id": 142027112,
                "url": "https://finnhub.io/api/news?id=84b153f090a71c431fea81e01b518e0994f3227a53423f24be4277a3873b5adf",
                "image": "",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Leerink Partners  analyst Daniel Clark   initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $20.",
                "category": "company",
                "datetime": 1788954210,
                "headline": "Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20"
              },
              {
                "id": 141954807,
                "url": "https://finnhub.io/api/news?id=5096a91b4f333c730ccfe0e68a86b9ee9dc5dd263c7795a6a8e0f8c711aa0f62",
                "image": "",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Argus Research  analyst Jasper Hellweg   maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $15 to $20.",
                "category": "company",
                "datetime": 1788857427,
                "headline": "Argus Research Maintains Buy on Viatris, Raises Price Target to $20"
              },
              {
                "id": 141376751,
                "url": "https://finnhub.io/api/news?id=d118cf1ab3728ebf1b85979981ec53e439dc21f0386a451d7ff93199e67f6195",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "The recent breakout of Moderna reminded investors that AI stocks aren’t the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We ran an analysis based on Insider Monkey’s proprietary database of over 900 hedge funds to see which healthcare stocks trading under $20 billionaire-led funds were holding […]",
                "category": "company",
                "datetime": 1788358558,
                "headline": "Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks"
              },
              {
                "id": 141365291,
                "url": "https://finnhub.io/api/news?id=6070e2474437d427d3022ac895cc5dbcd48786d6f1b16a63289e3dbbef41b79e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Amphastar Pharmaceuticals, Sandoz and Viatris are positioned to benefit from new launches, biosimilars and a shift toward higher-value generics.",
                "category": "company",
                "datetime": 1788192600,
                "headline": "Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris"
              },
              {
                "id": 141365292,
                "url": "https://finnhub.io/api/news?id=a369436408ea17a34a5c4eb6d2dcc285ffd91f1aa7d04ca0cec417677e2e73a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
                "category": "company",
                "datetime": 1788188304,
                "headline": "3 Cash-Producing Stocks That Concern Us"
              },
              {
                "id": 141365293,
                "url": "https://finnhub.io/api/news?id=0cfe80e9f499516427ef257e6ba453fe5c12a498ea2cf0aefb7607639c325b97",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Why recent generic drug earnings matter for Viatris stock Recent earnings across the generic drug industry highlighted steady demand alongside pricing and supply challenges, putting fresh attention on how Viatris (VTRS) is using new launches, product mix, and cost discipline to support its business. At a share price of US$16.34, Viatris has seen some short term pressure, with the 1 day share price return declining 3.26% and the 1 month share price return down 8.31%. However, the year to date...",
                "category": "company",
                "datetime": 1787994714,
                "headline": "Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough?"
              },
              {
                "id": 141337975,
                "url": "https://finnhub.io/api/news?id=f0b549d8871ca7c8d78bf091cb4bd1060ad6e8fdf82d785ccf200b1d7ea26a8b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/910130768/image_910130768.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "Analyze 10-year “Dividend Dogs” yield strategy: 89 picks, safer high-yield stocks, and 2027 gain targets with cash-flow risk checks.",
                "category": "company",
                "datetime": 1787915848,
                "headline": "17 Ideal 'Safer' Buyable August Dogs Dug Up After 10 Years"
              },
              {
                "id": 141361751,
                "url": "https://finnhub.io/api/news?id=72a4944f3ea119a7d72978f23ccc21a27f74cf270ce4c4aea8b96485c296b73d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential...",
                "category": "company",
                "datetime": 1787912100,
                "headline": "Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris"
              },
              {
                "id": 141365294,
                "url": "https://finnhub.io/api/news?id=963baebf07640d9334ca5efcd647374b5f7f149f227119866255b3b32d064fc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.",
                "category": "company",
                "datetime": 1787853960,
                "headline": "3 Generic Drug Stocks to Watch Amid Improving Industry Trends"
              },
              {
                "id": 141363823,
                "url": "https://finnhub.io/api/news?id=9c8b2f0475dfd629297bfae048b5d5f5ea0c0283c0bbe783b6963f9920c593ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Forget the humanoid robots for a minute; the most potent catalyst for the stock may already be hitting the streets, and it's growing exponentially.",
                "category": "company",
                "datetime": 1787694070,
                "headline": "The Real Engine That Could Power Tesla Stock Higher"
              },
              {
                "id": 141363824,
                "url": "https://finnhub.io/api/news?id=e3a8a5bb3823204b5a19852a30790976d7abfb4d213c0dc8bde136adcb75e836",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Management put a stunning new number on its full-year earnings, and the market is buying the story. But the real question is whether this is a new era of growth or customers pulling forward tomorrow's demand into today.",
                "category": "company",
                "datetime": 1787692827,
                "headline": "Dell Stock's Massive Guidance Raise Has A Catch"
              },
              {
                "id": 141284772,
                "url": "https://finnhub.io/api/news?id=5bc8e4e50fa4ab7fcbd6c0255b4199e7a71378d96c4a53c2032ccd6367a112f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris' (VTRS) China business remains resilient despite concerns over the country's new volume-cont",
                "category": "company",
                "datetime": 1787159803,
                "headline": "Viatris' China Policy Concerns Overstated, UBS Says"
              },
              {
                "id": 141256563,
                "url": "https://finnhub.io/api/news?id=47d09a8476c623adbf2dd3736020afd2add585adc875602b103f3b161446df6a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.",
                "category": "company",
                "datetime": 1787144282,
                "headline": "3 S&P 500 Stocks We Keep Off Our Radar"
              },
              {
                "id": 141254794,
                "url": "https://finnhub.io/api/news?id=55c5d4cc08059beb24bfeec80d4e20958cb1f53dc8060d9936946eff2ac9803f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.",
                "category": "company",
                "datetime": 1787060733,
                "headline": "3 Stocks Under $50 We’re Skeptical Of"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 1,
            "negative_hits": 0,
            "positive_hits": 0,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 20,
            "discarded_article_count": 19
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 21.2,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 3,
          "vcpPoints": 2.2,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(14.7%→6.6%)；跌縮量(近10日6日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 9085440,
              "down_days": 6,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 7620810,
              "avg_vol_20": 7314250,
              "avg_vol_30": 9085440,
              "range_pct_10": 0.06596614127262129,
              "range_pct_20": 0.07589025102159958,
              "range_pct_30": 0.14652656158785757,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8387937183009299,
              "dist_to_20d_high": 0.008680555555555679,
              "down_shrink_days": 6,
              "breakout_level_20d": 17.28,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.45019920318725204
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 3.2,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.433158201984822,
              "turnoverUsdM": 114.84947252999999,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.VTRS",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 16.2964,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 4.9,
            "take_profit_price": 18.1067,
            "target_multiplier": 1.9,
            "technical_strength": 1.85,
            "take_profit_percent": 5.7
          },
          "positionPoints": 1.4,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.866316403969644,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 0.4168,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.43
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 160.89
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1982
    },
    "kdj": {
      "d": 53.18,
      "j": 85.84,
      "k": 64.07,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 53.01
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 2025581,
      "recentSlope": 205388.1,
      "previousSlope": 4643700
    },
    "rsi": 54.32,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 10,
      "trend": "上升",
      "value": 16.15,
      "position": "SAR由上轉下+趨勢強",
      "distancePct": 5.72,
      "previousTrend": "下降"
    },
    "ma50": 16.7986,
    "macd": {
      "macd": 0.05174767234377242,
      "trend": "強烈看漲",
      "signal": 0.00044882528662085544,
      "histogram": 0.05129884705715157
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 8,
      "value": 16.6467,
      "position": "連續3日>VWAP",
      "consecutiveAbove": 4
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.91,
      "score": 4,
      "avgVolume": 7365639,
      "currentVolume": 6704581
    },
    "derived": {
      "ma20": 16.6645,
      "ma50": 16.7986,
      "prevClose": 17.02,
      "avgVolume10": 7507948,
      "avgVolume20": 7365639,
      "changePercent": 0.65,
      "avgVolumeForScore": 7365639
    },
    "ma_cross": {
      "ma20": 16.6645,
      "ma50": 16.7986,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 16.6205,
      "prevMa50": 16.7892,
      "spreadPct": 0.8,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 16.1295,
      "upper": 17.1995,
      "position": "上半部"
    },
    "rsi_short": 85.39,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.91
    }
  }
}

{
  "close": 17.13,
  "volume": 6704581,
  "changePercent": 0.65
}